5-((2-(1H-Imidazol-5-yl)ethyl)amino)-5-oxopentanoic acid

Catalog No. :
ACEFJB425
CAS No. :
219694-63-0
Molecular Formula :
C10H15N3O3
Molecular Weight :
225.25

IUPAC Name:5-((2-(1H-imidazol-5-yl)ethyl)amino)-5-oxopentanoic acid

5-((2-(1H-Imidazol-5-yl)ethyl)amino)-5-oxopentanoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$71.00Login to see priceIn stockIn stock
1g95%$196.00Login to see priceIn stockIn stock
5g95%$804.00Login to see priceInquiryIn stock

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-((2-(1H-Imidazol-5-yl)ethyl)amino)-5-oxopentanoic acid
IUPAC Name5-((2-(1H-imidazol-5-yl)ethyl)amino)-5-oxopentanoic acid
MDL No.-
Molecular FormulaC10H15N3O3
Molecular Weight225.25
SMILESO=C(O)CCCC(NCCC1=CN=CN1)=O
InChI KeyKZIMLUFVKJLCCH-UHFFFAOYSA-N
SynonymPentanoic acid, 5-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-oxo-;4-{[2-(1H-imidazol-5-yl)ethyl]carbamoyl}butanoic acid;Ingavirin;Pentanoic acid, 5-[[2-(1H-imidazol-5-yl)ethyl]amino]-5-oxo-;Ingavirin-D6;5-((2-(1H-Imidazol-5-yl)ethyl)amino)-5-oxopentanoic acid
CAS No.219694-63-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364

Synthetic Route by SureRoute

1. ACEFJB425 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACNEWS712 route compound structure diagram
    ACNEWS71256-92-8 In Stock
  2. Plus
  3. ACDTRU046 route compound structure diagram
    ACDTRU046108-55-4 In Stock
  4. Then
  5. ACEFJB425 route product structure diagram
    ACEFJB425219694-63-0 In Stock
Inquiry

2. ACEFJB425 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACEFJB425 route product structure diagram
    ACEFJB425219694-63-0 In Stock
Inquiry

Comments (0)